Several immunotherapeutic strategies, including non-specific biological response modifiers [1], interleukin (IL)-2-activated lymphocytes [2], tumor-specific reactive CD8+ T-lymphocyte transfer [3,4], dendritic cell (DC) vaccines [5,6], and tumor-associated antigen (TAA)-derived peptides [7,8], have been used for cancer treatment. Here, CD8A is linked to neoplasm.